Condition
Relapsed or Refractory B-cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Relapsed or Refractory B-cell Lymphoma clinical trials that are recruiting, at sites in 2 countries (most in China (1), Russia (1)). 1 was first registered in the last 30 days. By phase: Phase 4 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1New in 30 days
- 2Countries
All recruiting trials (2)
-
Holding/bridging therapy with a bispecific antibody before CAR-T in aggressive B-cell lymphoma
This study tests whether a short course of a CD20×CD3 bispecific antibody, given with GemOx or polatuzumab vedotin, helps patients with relapsed or refractory aggressive B-cell lymphoma proceed to planned CD19 CAR-T therapy.
-
Second infusion of relma-cel for patients with relapsed B-cell lymphoma
This study tests if giving a second dose of relma-cel can help adults with relapsed large B-cell lymphoma who have already had this treatment before.
Related topics
Quick answers
How many Relapsed or Refractory B-cell Lymphoma clinical trials are recruiting right now?
2, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (1 trial), Russia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.